ProQR Therapeutics N.V.

NasdaqCM PRQR

ProQR Therapeutics N.V. Market Capitalization on January 14, 2025: USD 239.35 M

ProQR Therapeutics N.V. Market Capitalization is USD 239.35 M on January 14, 2025, a -5.91% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • ProQR Therapeutics N.V. 52-week high Market Capitalization is USD 475.52 M on October 17, 2024, which is 98.67% above the current Market Capitalization.
  • ProQR Therapeutics N.V. 52-week low Market Capitalization is USD 173.49 M on July 03, 2024, which is -27.52% below the current Market Capitalization.
  • ProQR Therapeutics N.V. average Market Capitalization for the last 52 weeks is USD 241.57 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NasdaqCM: PRQR

ProQR Therapeutics N.V.

CEO Mr. Daniel Anton de Boer
IPO Date Sept. 18, 2014
Location Netherlands
Headquarters Zernikedreef 9
Employees 156
Sector Health Care
Industries
Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Similar companies

WVE

Wave Life Sciences Ltd.

USD 11.13

-1.24%

TIL

Instil Bio, Inc.

USD 20.03

5.31%

CTMX

CytomX Therapeutics, Inc.

USD 0.84

-5.23%

ASMB

Assembly Biosciences, Inc.

USD 14.74

-1.01%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

NUVB

Nuvation Bio Inc.

USD 2.59

-3.00%

ANNX

Annexon, Inc.

USD 4.53

-8.30%

APLS

Apellis Pharmaceuticals, Inc.

USD 27.69

-3.15%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

ALNY

Alnylam Pharmaceuticals, Inc.

USD 240.51

-6.88%

ARWR

Arrowhead Pharmaceuticals, Inc.

USD 18.05

-4.55%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

StockViz Staff

January 15, 2025

Any question? Send us an email